Abstract
For large hypofractionated treatment schemes in brachytherapy (1), accurate and precise dose verification is important for optimizing dose delivery and monitoring the dose in the organs at risk. Our work reported preliminary results for the in vivo dose verification of transperineal ultrasound (TRUS) guided 192Ir high dose rate (HDR) brachytherapy with computed tomography–based treatment planning. The choice of LiF:Mg,Ti emanates from the fact that this material has been widely used and accepted by the brachytherapy society for the experimental dosimetry of 192Ir brachytherapy sources (2–6); it has been compared with extensive Monte Carlo calculations (5, 6) as well as diode measurements for 192Ir HDR brachytherapy (5, 6), and has also been recently applied for the urethral dosimetry of prostate 192Ir HDR brachytherapy (7).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
